Microbix Biosystems Inc. (MBXBF)' Revenue Increases 35% in Third Quarter
8/14/2013 10:10:56 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TORONTO, Aug. 14, 2013 /CNW/ - Microbix Biosystems Inc. (TSX: MBX), a biotechnology company developing innovative biological products and technologies, today reported financial results for its third quarter ending June 30, 2013. Revenue was $1,906,652 compared to $1,413,531 for the same quarter last year, an increase of 35%. This increase is the result of continued growth in antigen sales in the quarter and ongoing consulting services provided to Zydus under the Kinlytic® license agreement. Operating expenses for the quarter were $1,026,841 compared to $1,437,660 for the same quarter last year, a reduction of $410,819.
Help employers find you! Check out all the jobs and post your resume.